Successful Treatment of Vancomycin-resistant Enterococcus faecium Meningitis with Linezolid: Case Report and Literature Review

References

• Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997; 29: 95–102.
   PubMed Web of Science ®Google Scholar
• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157–61.
   PubMed Web of Science ®Google Scholar
• Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1: 57–8.
   PubMed Web of Science ®Google Scholar
• Stevenson KB, Murray EW, Sarubbi FA. Enterococcal meningitis: report of four cases and review. Clin Infect Dis 1994; 18: 233–9.
   PubMed Web of Science ®Google Scholar
• Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710–21.
   PubMed Web of Science ®Google Scholar
• Zanella RC, Valdetaro F, Lovgren M, Tyrrel GJ, Bokermann S, Almeida SC, et al. First confirmed case of a vancomycin-resistant Enterococcus faecium with vanA phenotype from Brazil: Isolation from a meningitis case in Sao Paulo. Microb Drug Resist 1999; 5: 159–62.
   PubMedGoogle Scholar
• Perez Mato S, Robinson S, Begue RE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pediatr Infect Dis J 1999; 18: 483–4.
   Google Scholar
• Stahl JP, Croize J, Wolff M, Garaud JJ, Leclercq P, Vachon F, et al. Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis. J Antimicrob Chemother 1987; 20: 141–2.
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Wolf A, Schwalbe RS, Nataro J, Gibson CB, Lewis EW. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994; 19: 163–5.
   PubMed Web of Science ®Google Scholar
• Dever LL, Smith SM, Dejesus D, Masurekar M, Patel D, Kaminski ZC, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Microb Drug Resist 1996; 2: 407–13.
   PubMed Web of Science ®Google Scholar
• Koc Y, Snydman DR, Schenkein DS, Miller KB. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 1998; 22: 207–9.
   PubMed Web of Science ®Google Scholar
• Gransden WR, King A, Marossy D, Rosenthal E. Quinupristin/dalfopristin in neonatal Enterococcus faecium meningitis [letter]. Arch Dis Child Fetal Neonatal Ed 1998; 78: F235–6.
   PubMed Web of Science ®Google Scholar
• Nachman SA, Phillips A, Gray SL, Talbot GH. Treatment of vancomycin resistant Enterococcus faecium central nervous system infection with intrathecal administration of quinupristin/dalfopristin. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24–27 September, 1998, San Diego, CA. Washington D.C.: American Society of Microbiology; 1998 [abstract E–167].
   Google Scholar
• Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb Drug Resist 1995; 1: 95–6.
   Google Scholar
• Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinipristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998; 26: 1460–1.
   PubMed Web of Science ®Google Scholar
• Tan TY, Pitman I, Penrose-Stevens A, Simpson BA, Flanagan PG. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. J Infect 2000; 41: 95–7.
   Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251–5.
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45.
   PubMed Web of Science ®Google Scholar
• Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ Jr, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996; 40: 1508–13.
   Google Scholar
• Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1999; 34: 119–22.
   PubMed Web of Science ®Google Scholar
• Clemett D, Markham A. Linezolid. Drugs 2000; 59: 815–27.
   PubMed Web of Science ®Google Scholar
• Zyvox [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Company, 2000.
   Google Scholar
• Zyvox (linezolid). Brochure for the anti-infective drug products advisory committee meeting, 24 March, 2000. Available from http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3597b1.htm (accessed 26 January, 2001).
   Google Scholar
• Rayner CR, Forrest A, Meagher AK, Birmingham MC. Population pharmacodynamics of linezolid in seriously-ill adult patients from a compassionate-use protocol. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1720 September, 2000, Toronto, Ont., Canada. Washington D. C.: American Society of Microbiology, 2000 [abstract 1390].
   Google Scholar